Table 1.

Characteristics of NMOSD patients (#1–14) and HC (#15–33).

#	Age	Onset	EDSS	No. of relapses	Current medication	AQP4(x) IgG	MOG- IgG	AMH ng/ml	Birth control	Children
1	25–30	2006	7	29	Tocilizumab	+	–	0.457	–	–
2	40–45	2006	6	2	Teriflunomide	+	–	6.543	–	–
3	40–45	2010	7.5	9	Tocilizumab	+	–	0.827	–	–
4	35–40	2008	5	10	Azathioprin	–	–	0.211	–	–
5	30–35	2007	2.5	11	Rituximab	+	–	0.765	+	–
6	35–40	2013	4	8	DMF	–	–	2.928	+	+
7	20–25	2014	1.5	3	Rituximab	–	+	1.821	+	–
8	20–25	2008	1.5	2	Azathioprin	+	–	3.538	+	+
9	20–25	2015	2	2	Rituximab	+	–	1.456	+	–
10	30–35	2011	2.5	1	Rituximab	+	–	1.335	–	–
11	15–20	2010	3.5	5	Azathioprin	+	–	4.235	–	–
12	40–45	2014	1	1	Rituximab	+	–	0.511	–	–
13	40–45	2010	1	8	Azathioprin	+	–	2.187	–	+
14	35–40	2009	2.5	4	Azathioprin	+	–	2.940	–	–
15	30–35	x	x	x	None	x	x	3.779	+	+
16	40–45	x	x	x	None	x	x	1.191	–	–
17	40–45	x	x	x	None	x	x	0.892	–	+
18	35–40	x	x	x	None	x	x	0.648	–	–
19	30–35	x	x	x	None	x	x	1.875	–	–
20	40–45	x	x	x	None	x	x	0.909	–	–
21	20–25	x	x	x	None	x	x	4.936	+	–
22	20–25	x	x	x	None	x	x	4.901	+	–
23	30–35	x	x	x	None	x	x	4.304	–	–
24	30–35	x	x	x	None	x	x	6.394	–	–
25	20–25	x	x	x	None	x	x	3.922	+	–
26	30–35	x	x	x	None	x	x	1.496	+	–
27	30–35	x	x	x	None	x	x	2.418	–	–
28	40–45	x	x	x	None	x	x	0.929	–	–
29	25–30	x	x	x	None	x	x	7.057	+	–
30	30–35	x	x	x	None	x	x	5.623	+	+
31	20–25	x	x	x	None	x	x	2.461	+	–
32	25–30	x	x	x	None	x	x	4.757	+	–

In order to protect patients identify and in accordance with journal regulations the patient's age is presented as a range. Dimethyl fumarate (DMF).